10th International Congress on Drug Therapy in HIV Infection, 7-11 November 2010, Glasgow
The Glasgow conference is held every two years and attracts a broad interest from both European and US clinicians and researchers.
This year the conference abstracts are already posted online as a supplement to the Journal of the International AIDS Society (Volume 13, Supplement 4).
In the references to our reports we include both the conference abstract numbers and the IAS publication link.
A PDF file of the abstracts is also available (direct download): http://www.biomedcentral.com/content/files/pdf/1758-2652-13-S4-full.pdf
Approximately 200 posters are online as PDF files, categorised by general topics, and posted to the webcast pages of the conference website. A few webcasts are included in this selection.
Reports in this issue include:
- Virological findings from the SARA trial of boosted protease inhibitor monotherapy
- Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
- Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
- High preterm delivery rates associated with initiation of HAART during pregnancy at a London clinic
- Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
- The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure
- Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children
- Efavirenz versus nevirapine based first line treatment in a South African cohort
- GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
- Consensus guidelines recommend routine use of genotypic tropism testing for European patients prior to using maraviroc
- UK studies on bone health: increased fracture rates reported in HIV-positive people
- Muscle weakness or pain analysed as possible raltegravir side effect
- Adding maraviroc does not boost CD4s in randomised trial
- Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
- Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350